Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 10,729 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Interventions
PM359
Biological
Lead sponsor
Prime Medicine, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Nashville, Tennessee
Conditions
Primary Myelofibrosis, Fibrosis, Bone Marrow
Interventions
IPI-926
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Palo Alto, California • Houston, Texas
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Dual-Energy Computed Tomography, Echocardiography, Fludarabine, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Partially Engineered T-regulatory Cell Donor Graft TRGFT-201, Tacrolimus, Thiotepa, Total Marrow and Lymphoid Irradiation
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Duarte, California
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Conditions
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
Interventions
AMG 176, Azacitidine, Itraconazole
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 7 more
Conditions
Anemia
Interventions
ferumoxytol, moxifloxacin, placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Multiple Myeloma
Interventions
Arlocabtagene Autoleucel
Biological
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more
Conditions
Sepsis, Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
AFX-2
Drug
Lead sponsor
Afexa Life Sciences Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Winston-Salem, North Carolina • Greenville, South Carolina
Conditions
Leukemia
Interventions
filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Nebraska
Other
Eligibility
1 Year to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Thrombocytopenia, Metachromatic Leukodystrophy, Fanconi's Anemia, Thalassemia Major, Pure Red-Cell Aplasia, Inborn Errors of Metabolism
Interventions
Stem Cell Transplantation
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Interventions
HSCT with TBI Regimen, HSCT with Non-TBI Regimen
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Interventions
Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway
Other
Lead sponsor
All4Cure
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
Conditions
Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand Factor (rVWF)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Miami, Florida • Augusta, Georgia + 8 more
Completed Phase 2 Interventional Results available

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
Conditions
Acute Lymphoblastic Leukemia
Interventions
Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
No Intervention
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Leukemia, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin's
Interventions
PedsQL Cancer Module, PedsQL Multidimensional Fatigue Scale, Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, Test of Motor Proficiency, Verbal Numeric Pain Scale, :Yoga Therapy
Other · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
cyclophosphamide, fludarabine phosphate, vincristine sulfate, prednisone, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT01658904
Conditions
Multiple Myeloma, Leukemia, Plasma Cell
Interventions
Carfilzomib, Melphalan, Filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab with FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Baltimore, Maryland + 2 more
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
134 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California